Dual immunotherapy plus lenvatinib shows early promise in endometrial cancer
A small single-arm trial of the PD-1/CTLA-4 antibody cadonilimab with lenvatinib reported a 40.6% response rate in previously treated advanced endometrial cancer.
Adding atezolizumab to chemo did not clearly help early triple-negative breast cancer
In the NSABP B-59 trial, adding the immunotherapy to neoadjuvant chemotherapy did not significantly improve event-free survival, while immune-related side effects more than doubled.
An mRNA cancer vaccine just won a late-stage trial. Here is what that actually means.
Moderna and Merck's personalized vaccine slowed melanoma's return when added to Keytruda. It is the first mRNA cancer vaccine to succeed at scale — and the first real test of a decade-old idea.
An off-the-shelf cancer vaccine provoked an immune response in every person who got it
Nous-209 targets 209 mutations shared across a whole class of tumours, so it can be manufactured in advance. What the trial has not yet shown is that anyone got less cancer.
An off-the-shelf COVID mRNA vaccine made cold tumours respond in mice
The Nature paper pairs mouse mechanism with retrospective human cohorts: vaccination within 100 days of starting a checkpoint inhibitor was associated with better survival. Retrospective is the load-bearing word.